Alfibercept在眼科的应用研究进展被引量：3

Current advance in the application of Alfibercept in ophthalmology

下载PDF

导出

摘要 Alfibercept是一种新型抗血管内皮生长因子（VEGF）药物，它能与VEGF—A和VEGF—B的所有亚型以及胎盘生长因子（PIGF）相结合。目前Alfibercept已被玻璃体腔注药治疗一些眼科疾病，如新生血管性年龄相关性黄斑变性（NAMD）、息肉状脉络膜血管病变（PCV）、视网膜中央静脉阻塞（CRVO）、糖尿病黄斑水肿（DME）、角膜新生血管及早产儿视网膜病变（ROP）等。本文将Alfibercept和其他抗VEGF药物比较，并就其在眼科疾病中的研究进展予以综述，最后提出了Alfibercept在眼科疾病的治疗中需要解决的问题和今后的研究方向。 As the newest anti-vascular endothelial grown factor （VEGF） drug, alfibereept binds to all forms of VEGF-A, VEGF-B, and PIGF. So far, intravitreal injection of alfibercept has already been used to treat certain opthalmological diseases, such as neovascular age-related macular degeneration, polypoidal choroidal vasculopathy, central retinal vascular occlusion,diabetic macular edema,corneal neovascular, and retinopathy of prematurity. In this article,we contrasted alfibercept to the other anti-VEGF drugs,conducted a review of the recent research progress of alfibercept in opthalmological diseases and introduced the questions which still need to be solved and the probably research direction of alfibereept in the future.

作者陈曦解正高

机构地区扬州大学临床医学院眼科苏北人民医院眼科

出处《中华实验眼科杂志》 CAS CSCD 北大核心 2015年第12期1144-1147,共4页 Chinese Journal Of Experimental Ophthalmology

关键词 Alfibercept 血管内皮生长因子玻璃体腔注射年龄相关性黄斑变性 Alfibercept Vascular endothelial growth factor lntravitreal injection Age-related macular degeneration

分类号 R77 [医药卫生—眼科]

引文网络
相关文献

参考文献36

1Chang JH, Garg NK, Lunde E, et al. Corneal neovascularization : an anti- VEGF therapy review [ J ]. Surv Ophthahnol, 2012,57 ( 5 ) : 415 -429. doi : 10. 1016/j. survophthal. 2012.01. 007.
2Ohr M ,Kaiser PK. Aflibercept in wet age-related maeular degeneration: a perspective review[J]. Ther Adv Chronic Dis,2012,3(4) : 153-161. doi: 10.1177/2040622312446007.
3Sophie R, Akhtar A, Sepah YJ, et al. Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases [ J/OL ]. Biol Ther,2012,2 : 3 [ 2015 -04- 18 ]. http://www, ncbi. nlm. nih. gov/pmc/articles/PMC3873045/# _ffn_ sectitle, doi: 10. 1007/s13554- 012-0003-4.
4Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology[ J]. Mayo Clin Proc ,2012,87 ( 1 ) : 77-88. doi : 10. 1016/j. mayocp. 2011.10. 001.
5Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap [ J ]. Br J Ophthalmol, 2008,92 ( 5 ) : 667 - 668. doi : 10. 1136/bjo. 2007. 134874.
6Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap,ranibizumab and bevacizumab [ J ]. Angiogenesis, 2012, 15 ( 2 ) : 171 - 185. doi : 10. 1007/s10456-011-9249-6.
7Semeraro F, Morescalchi F, Duse S, et al. Aflibercept in wet AMD: specific role and optimal use [ J ]. Drug Des Devel Ther, 2013,7 : 711-722. doi : 10. 2147/DDDT. S40215.
8Saito M, Kano M ,Itagaki K,et al. Retinal pigment epithelium tear after intravitreal aflibercept injection [ J ]. Clin Ophthalmol,2013,7 : 1287-1289. doi: 10. 2147/OPTH. S47735.
9Ammar DA,Mandava N, Kahook MY. The effects of aflibercept on the viability and metabolism of ocular cells in vitro [ J ]. Retina,2013,33 (5) : 1056-1061. doi:10. 1097/IAE. 0b013e31827b646d.
10Schnichels S, Hagemann U, Januschowski K, et al. Comparative toxicity and proliferation testing of aflibercept,bevacizumab and ranibizumab on different ocular cells[ J ]. Br J Ophthalmol, 2013,97 ( 7 ) : 917 - 923. doi : 10.1156/bjophthalmol-2013-303130.